Hims Company Overview and Business Model

What Hims Actually Is

Hims & Hers Health operates a telehealth platform connecting patients with licensed providers through asynchronous questionnaire-based consultations. The company was founded in 2017 with a focus on men's health categories that many patients find embarrassing to discuss in person, particularly erectile dysfunction and androgenetic alopecia. It has since expanded to include women's health (under the Hers brand), mental health, dermatology, and weight management.

The platform does not employ physicians directly in most states. Instead, it contracts with affiliated medical groups staffed by independently licensed MDs, DOs, NPs, and PAs. Patients complete structured intake forms, upload photos when relevant, and receive a provider decision, often within 24 hours. If a prescription is issued, it ships from either an affiliated compounding pharmacy or a retail pharmacy partner. The subscription model auto-renews, which simplifies refills but has drawn consumer complaints to the FTC regarding cancellation friction.

From a regulatory standpoint, Hims operates within the same state-by-state licensure framework as any telehealth provider. Its pharmacies hold DEA registrations and state licenses. The platform is not an FDA-approved entity itself; rather, it facilitates access to FDA-approved medications and, in some cases, compounded formulations.

Business Model: Subscription D2C Telehealth

Hims generates revenue through monthly and quarterly subscriptions that bundle the consultation fee, medication cost, and shipping into a single price. This model eliminates the traditional insurance billing cycle entirely. Patients pay out of pocket.

The subscription approach has driven rapid growth. Hims reported $1.5 billion in revenue for 2024, up from $527 million in 2022, with over 2 million active subscribers. Gross margins typically exceed 75%, reflecting the low marginal cost of digital consultations and pharmacy fulfillment.

Three structural advantages define the model. First, asynchronous consultations require no appointment scheduling, reducing overhead per patient encounter. Second, auto-ship subscriptions create predictable recurring revenue and high lifetime value. Third, direct pharmacy relationships (including ownership of affiliated compounding pharmacies) allow vertical integration of the supply chain.

The tradeoff is clinical depth. Asynchronous visits lack the physical examination, lab review, and longitudinal relationship that characterize traditional endocrinology or urology care. The American Urological Association's 2018 guidelines on erectile dysfunction recommend a focused physical exam and targeted laboratory testing (fasting glucose, lipid panel, testosterone) as part of the initial evaluation. Whether questionnaire-based platforms consistently meet this standard is debated.

Erectile Dysfunction Treatments on Hims

Hims prescribes sildenafil (generic Viagra) and tadalafil (generic Cialis) as its primary ED offerings. Both are PDE5 inhibitors with strong evidence from randomized controlled trials. A meta-analysis of 130 RCTs (N=36,935) published in the British Medical Journal confirmed that PDE5 inhibitors produce clinically meaningful improvements in erectile function scores compared to placebo.

Pricing for sildenafil on Hims ranges from $2 to $4 per dose depending on subscription tier and quantity. Tadalafil daily (5 mg) runs approximately $30 to $50 per month. These prices are competitive with GoodRx discount pricing at retail pharmacies but higher than many insurance copays for generic PDE5 inhibitors.

Hims also offers compounded combination products, including formulations that pair sildenafil with oxytocin or apomorphine. Compounded medications are not FDA-approved as finished products, and the FDA has noted that compounded drugs do not undergo the same premarket review for safety, efficacy, and quality as approved drugs. Patients should understand this distinction before selecting a compounded option over a commercially available generic.

Hair Loss: Finasteride and Minoxidil Access

Androgenetic alopecia treatment is Hims' original flagship category. The platform prescribes oral finasteride (1 mg daily) and topical minoxidil (5%), both of which carry strong evidence. The landmark Kaufman et al. trial demonstrated that finasteride 1 mg daily increased hair count by a mean of 107 hairs per cm² over 2 years compared to a decline of 58 hairs per cm² with placebo (P<0.001) in a study of 1,553 men published in the European Journal of Dermatology.

Minoxidil 5% foam applied twice daily has been shown to produce superior results versus 2% solution. A 48-week RCT (N=352) published in the Journal of the American Academy of Dermatology found 5% topical minoxidil produced 45% more hair regrowth than the 2% formulation.

Hims also markets a topical finasteride-minoxidil combination spray. This compounded product bypasses first-pass hepatic metabolism, which may reduce systemic finasteride exposure. A 2022 study in the Journal of Drugs in Dermatology found that topical finasteride 0.25% achieved comparable scalp DHT reduction to oral finasteride 1 mg with lower serum DHT suppression. This is a reasonable option for patients concerned about systemic side effects, though long-term comparative efficacy data between topical and oral finasteride remains limited.

Monthly pricing for the Hims hair loss subscription ranges from $20 for standalone oral finasteride to $60 or more for combination topical products.

Men's Hormone Therapy and Testosterone

Hims entered the testosterone replacement therapy (TRT) space more recently, offering testosterone cypionate injections for men with clinically diagnosed hypogonadism. This is a significant clinical step beyond its earlier ED and hair loss offerings.

The Endocrine Society's 2018 Clinical Practice Guideline recommends TRT only for men with unequivocally low morning testosterone (confirmed on two separate measurements) combined with signs and symptoms of androgen deficiency. The guideline specifically advises against prescribing testosterone to men planning fertility in the near term, as exogenous testosterone suppresses spermatogenesis.

Whether asynchronous telehealth platforms can adequately evaluate TRT candidates is a legitimate clinical question. Proper TRT management requires baseline labs (total testosterone, free testosterone, LH, FSH, CBC, PSA, lipid panel, metabolic panel), follow-up labs at 3 and 6 months, and ongoing hematocrit monitoring given the risk of polycythemia. The T-Trials (N=790), published in the New England Journal of Medicine, demonstrated that testosterone gel improved sexual function, physical function, and mood in men 65 and older with low testosterone, but also showed increased coronary artery plaque volume in the cardiovascular sub-study.

More recently, the TRAVERSE trial (N=5,246), published in NEJM in 2023, found that testosterone replacement in men 45 to 80 years old with hypogonadism and cardiovascular risk factors did not increase the incidence of major adverse cardiovascular events compared to placebo. This was a key finding that addressed longstanding safety concerns.

Hims requires bloodwork before initiating TRT, though the depth of the clinical evaluation compared to a specialist visit varies by provider. Pricing for testosterone cypionate through Hims is approximately $60 to $150 per month, depending on dosing and frequency.

GLP-1 Weight Loss Offerings

In 2023, Hims began offering access to GLP-1 receptor agonists for weight management, initially through compounded semaglutide. The STEP-1 trial (N=1,961), published in the New England Journal of Medicine, showed that semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo.

Hims priced compounded semaglutide significantly below Novo Nordisk's branded Wegovy list price ($1,349/month), offering plans starting around $199 per month. This pricing strategy drove substantial subscriber growth in 2024.

The FDA issued guidance in 2024 regarding compounded semaglutide products, raising questions about the legal basis for compounding copies of commercially available drugs. The FDA's position is that compounders may only produce copies of drugs on the shortage list, and that semaglutide's shortage status has fluctuated. Patients using compounded GLP-1 products from any platform should monitor FDA shortage list updates, as regulatory enforcement actions could disrupt supply.

Mental Health Services

Hims prescribes SSRIs (sertraline, fluoxetine), SNRIs (desvenlafaxine), bupropion, and buspirone for anxiety and depression through its mental health vertical. The platform uses validated screening tools (PHQ-9 for depression, GAD-7 for anxiety) during the intake process.

A 2020 systematic review in JAMA Psychiatry found that telepsychiatry produced outcomes equivalent to in-person psychiatric care across multiple RCTs. This supports the general model, though the review primarily examined synchronous video visits rather than asynchronous questionnaire-based encounters.

The distinction matters. Synchronous video visits allow real-time assessment of affect, speech patterns, and suicidality risk. Asynchronous text-based consultations carry inherent limitations for mental health evaluation. Hims does offer video follow-ups for mental health subscribers, which partially addresses this concern.

How Hims Compares to Alternatives

The direct-to-consumer telehealth market for men's health includes Ro (Roman), Keeps, Vault Health, and traditional telehealth platforms like Teladoc and MDLive. Each occupies a slightly different niche.

Ro (Roman) operates a nearly identical model to Hims, with similar pricing, subscription structure, and product categories. Both use asynchronous consultations and affiliated pharmacies. Pricing differences between the two platforms are typically marginal ($2 to $10 per month depending on the product).

Keeps focuses exclusively on hair loss, offering finasteride and minoxidil at prices comparable to Hims but without the broader product portfolio.

Vault Health differentiates by requiring synchronous video consultations and mandatory lab work for all hormone therapy patients. This approach more closely mirrors traditional clinical practice and may be preferable for TRT candidates who want a more thorough evaluation.

Traditional brick-and-mortar urology or endocrinology offices offer comprehensive physical exams, in-house lab draws, and specialist expertise. They accept insurance, which can reduce out-of-pocket costs substantially. The tradeoff is scheduling delays (median wait time for a new urology appointment is 24 days, per a 2022 Merritt Hawkins survey) and the perceived stigma some patients associate with in-person visits for sensitive conditions.

The American Telemedicine Association's practice guidelines support telehealth as clinically appropriate for many primary care conditions, including straightforward ED and hair loss cases, provided the encounter meets the same standard of care as an in-person visit.

Is Hims Legitimate? Evaluating the Evidence

Hims is a publicly traded company (NYSE: HIMS) subject to SEC disclosure requirements, state medical board oversight, and pharmacy board regulation. It is not a scam. The medications it dispenses are real pharmaceuticals prescribed by licensed providers.

The more nuanced question is whether the quality of care matches what a patient would receive from a specialist. Several factors warrant consideration.

On the positive side, Hims removes access barriers. A 2021 study in JAMA Network Open found that only 25% of men with ED seek medical treatment, with embarrassment and access barriers cited as primary reasons. Platforms like Hims may reach patients who would otherwise go untreated.

On the other hand, the asynchronous model limits clinical evaluation. The Endocrine Society and AUA guidelines both presume a clinical encounter that includes physical examination and targeted laboratory assessment. Asynchronous questionnaires cannot palpate the thyroid, check testicular volume, or assess gynecomastia.

Consumer satisfaction data is mixed. Hims holds a 4.0 out of 5 rating on Trustpilot across over 30,000 reviews as of early 2026, with positive reviews citing convenience and effective medications, and negative reviews citing difficulty canceling subscriptions, limited provider interaction, and shipping delays.

Pricing Transparency and Hidden Costs

Hims advertises starting prices prominently, but total cost depends on product selection, dosing, and subscription tier. A representative pricing breakdown as of 2026:

ED (sildenafil, 10 tablets): $30/month. ED (tadalafil daily, 5 mg): $45/month. Hair loss (finasteride oral): $23/month. Hair loss (topical combo spray): $55/month. TRT (testosterone cypionate): $90 to $150/month. GLP-1 (compounded semaglutide, where available): $199+/month. Mental health (generic SSRI): $25/month.

Lab work for TRT is typically billed separately through a third-party lab (Quest or Labcorp), adding $50 to $150 per draw depending on the panel. Insurance does not cover Hims consultations or prescriptions dispensed through its affiliated pharmacies, so the full cost falls on the patient. For patients with commercial insurance, using a traditional provider and retail pharmacy with insurance billing may be less expensive for generic medications like sildenafil, finasteride, or sertraline.